Last reviewed · How we verify
NCT02066077
The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy
NA trial testing Etomidate in Major Depressive Disorder in 280 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | Shanghai Mental Health Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 280 |
| Start date | 1 January 2013 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 1 location across China |
Drugs / interventions tested
- Etomidate (ETOMIDATE) — full drug profile →
- Propofol (Propofol) — full drug profile →
- Bilateral temporal MECT
- The right temporal MECT
- Bilateral frontal MECT
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
Shanghai Mental Health Center — full company profile →
Who can join
18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. To determine the influencing factors of modified electroconvulsive therapy (MECT); 2. To determine the influencing factors and reversibility of the cognitive impairment caused by MECT; 3. To determine the duration of efficacy of MECT and its affecting factors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02066077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Etomidate
Trials testing the same drug.
- NCT04291521 — Prospective Study of Induction Medications Used in the Trauma RSI · not yet recruiting
- NCT07012902 — Relationship Between Remimazolam and Etomidate in Induction of General Anesthesia · EARLY_PHASE1 · not yet recruiting
- NCT06664138 — Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment · Phase 4 · completed
- NCT05277896 — Randomized Trial of Sedative Choice for Intubation · Phase 4 · completed
- NCT04934410 — Induction Agent and Incidence of Hypotension in Heart Failure Patients Undergoing LVAD-Implantation · unknown
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other Shanghai Mental Health Center trials
Trials by the same sponsor.
- NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
- NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
- NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
- NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
- NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02066077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
- Last refreshed: 23 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02066077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing